TOKYO, Japan and CAMBRIDGE, United Kingdom | January 19, 2026 — Nxera Pharma Co., Ltd. announced positive top-line results from a Phase 3 clinical trial of daridorexant 50 mg in adult and elderly patients with insomnia in South Korea. The randomized, double-blind, placebo-controlled study met all primary and secondary efficacy endpoints, positioning daridorexant for a planned marketing authorization application (MAA) submission in South Korea in Q1 2026, with regulatory approval anticipated in Q1 2027.
Science Significance
Scientifically, the results reinforce the clinical value of dual orexin receptor antagonism (DORA) as a targeted mechanism for treating insomnia. Daridorexant acts by equipotently inhibiting orexin receptors OX1R and OX2R, reducing excessive wake signaling that characterizes chronic insomnia. In the Phase 3 trial, daridorexant delivered statistically significant improvements in subjective total sleep time (sTST) as well as key secondary endpoints, including subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO) at Day 28. Importantly, these improvements were achieved without an increase in next-day residual effects, supporting the hypothesis that physiology-aligned modulation of wakefulness can improve sleep quality while maintaining daytime functioning.
Regulatory Significance
From a regulatory and cGxP standpoint, the successful Phase 3 outcome represents a pivotal milestone under Good Clinical Practice (GCP), enabling Nxera to advance toward formal regulatory review in South Korea. The trial’s multicenter, randomized, double-blind design and clearly met endpoints provide a robust evidence base for benefit–risk assessment by health authorities. Daridorexant is already approved and marketed in Japan as QUVIVIQ®, supporting regulatory confidence through cross-regional clinical consistency. The planned MAA submission in Q1 2026 reflects Nxera’s readiness to transition from development to regulatory evaluation, a critical inflection point in the drug lifecycle.
Business Significance
Advertisement
Commercially, the positive Phase 3 readout strengthens Nxera’s position in the high-value CNS and sleep-disorder market in South Korea, where insomnia affects an estimated 15–25% of adults, representing up to 11 million patients. Daridorexant’s differentiated profile and prior approvals in Japan, the U.S., and Europe create a strong platform for regional expansion in Asia-Pacific. For Nxera, advancing daridorexant also demonstrates the productivity of its NxWave™ GPCR structure-based discovery platform, enhancing corporate credibility with partners, investors, and regulators. A successful South Korean approval could unlock meaningful revenue opportunities while reinforcing Nxera’s strategy of building a specialty-focused commercial footprint across Asia.
Patients’ Significance
For patients, the findings are particularly meaningful given the chronic, debilitating nature of insomnia, which significantly impairs cognitive function, mood, and overall quality of life. Current pharmacologic treatments can be limited by tolerability issues, residual sedation, or dependence concerns. Daridorexant’s ability to improve sleep onset and maintenance with a safety profile comparable to placebo offers the potential for a more patient-friendly long-term therapy. In South Korea, where the burden of insomnia is rising — especially among older adults — access to an effective, well-tolerated treatment could translate into better daytime functioning, reduced healthcare utilization, and improved overall wellbeing.
Policy Significance
At a policy level, the trial underscores growing regulatory and public health emphasis on sleep disorders as a serious, chronic medical condition rather than a lifestyle issue. Demonstrating clear efficacy and safety in a large, well-controlled Phase 3 trial supports evidence-based policymaking around reimbursement, clinical guidelines, and access to novel CNS therapies. The development of daridorexant also reflects broader regulatory support for mechanism-driven therapies that target underlying disease biology, aligning with global trends toward precision pharmacology and patient-centered drug development.
Nxera’s positive Phase 3 results for daridorexant in South Korea mark a significant step forward in the clinical development of next-generation insomnia therapies. With robust efficacy across key sleep parameters, a favorable safety profile, and a clear regulatory pathway ahead, daridorexant is positioned to address a substantial unmet medical need in a large and growing patient population. For the cGxP community, the announcement highlights the importance of rigorous late-stage clinical execution, regulatory readiness, and translational science in delivering innovative CNS medicines from discovery to real-world impact.
Source: Nxera Pharma Co., Ltd. press release
